関連する実験動画

Updated: Jan 8, 2026

Modeling the Functional Network for Spatial Navigation in the Human Brain
05:55

Modeling the Functional Network for Spatial Navigation in the Human Brain

Published on: October 13, 2023

1.4K

Spatiotemporal Network Dynamics Reveal Alzheimer

Theodore J LaGrow1,2, Vaibhavi Itkyal3,4, Harrison Watters4

  • 1School of Electrical and Computer Engineering, Georgia Institute of Technology, 777 Atlantic Dr NW, Atlanta, GA 30332.

bioRxiv : the preprint server for biology
|December 22, 2025
PubMed
まとめ

新しい手法により、認知機能低下前にアルツハイマー病（AD）のネットワーク変化が早期に明らかになります。準周期的パターン（QPP）と複雑主成分分析（cPCA）は、早期AD検出の可能性のある微妙な脳の変化を検出します。

さらに関連する動画

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.1K
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.3K

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744